Comparative Pharmacology
Head-to-head clinical analysis: MONODOX versus NUZYRA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MONODOX versus NUZYRA.
MONODOX vs NUZYRA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
Omadacycline is a aminomethylcycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking aminoacyl-tRNA binding to the A site.
100 mg orally or IV every 12 hours on day 1, then 100 mg orally or IV every 24 hours; for severe infections, 100 mg every 12 hours.
200 mg intravenously once on day 1, then 100 mg IV once daily; or 200 mg orally once on day 1, then 100 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life: 14-22 hours (mean ~18 hours) in adults; prolonged up to 24-48 hours in renal impairment; no dose adjustment in mild-moderate renal impairment but caution in severe (CrCl <30 mL/min).
Terminal elimination half-life is approximately 17-21 hours; supports once-daily dosing.
Renal: ~40% (glomerular filtration, tubular secretion); biliary: ~20-60% (enterohepatic circulation); fecal: ~30% (unabsorbed or excreted in bile).
Fecal (approximately 76%) as unchanged drug; renal (approximately 14%) as unchanged drug; biliary excretion is minimal.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic